Nexgel (NXGL) Q1 2026 Earnings Transcript

Image source: The Motley Fool.

DATE

Friday, May 15, 2026 astatine 12 p.m. ET

CALL PARTICIPANTS

• Chief Executive Officer — Adam R. Levy

• Chief Financial Officer — Ian Blackman

Need a punctuation from a Motley Fool analyst? Email [email protected]

Full Conference Call Transcript

Adam R. Levy: Thank you, Valter, and convey you, everyone, for joining america today. On today's call, I would similar to supply an overview of our archetypal 4th 20 fiscal results and bring everyone up to velocity connected the advancement we person made connected the integration of the acquisition we precocious closed successful mid April. Starting with our archetypal 4th results, gross for the archetypal 4th totaled 2.65 cardinal arsenic compared to 2.81 cardinal for the aforesaid play past year. The concern year-over-year was comparatively flat, with income from Silly George coming successful lower, which were partially offset by gross maturation successful some declaration manufacturing and our MEDAGEL brand.

During the quarter, the summation successful our SG&A was owed chiefly to costs incurred relating to the acquisition of our BioNX part and the KISS Nail Products ineligible lawsuit which has since been settled. Cash and restricted currency arsenic of 03/31/2026 was astir $2.1 million. As of today, our currency connected manus is $1.8 million. In total, we person raised $13.8 cardinal comprised of $8.8 cardinal received successful cash, and $5 cardinal of our convertible enactment delivered to Cellularity to money the acquisition and to supply the concern with moving capital. The archetypal 4th does not see immoderate gross from our acquisition.

In the 2nd quarter, we person already seen income from Silly George normalize and recover, and we volition statesman accounting for gross from our acquisition for astir fractional of the 2nd quarter. The financing for BioNX was led by Sequence LifeScience, with a $5.5 cardinal concern that not lone fortify the financing operation of the transaction, but besides aligns america with a spouse that enhances our capabilities crossed manufacturing, merchandise development, and distribution. Importantly, this transaction replaced a fiscal lender who was seeking a adjacent word exit with a agelong word strategical spouse who is focused connected supporting the agelong word maturation and execution of our business. Brian J. Keeser and Kevin Harris, CEO and COO of Sequence LifeScience.

Have since joined our committee of directors. Brian and Kevin bring heavy manufacture experience, merchandise innovation, and a beardown organisation web that volition assistance america turn and grow the imaginable of our caller acquisition. I americium precise excited to person them successful our country and I americium looking guardant to moving with them to turn the business. The BioNX portfolio includes 6 established regenerative biomaterial products positioning america squarely wrong 1 of the fastest increasing segments of wellness care. These are not aboriginal signifier assets, They are commercialized signifier products with much than a decennary of objective use, demonstrated existent satellite utility, and already person existing reimbursement pathways.